Wuxi AppTec recently released its Q3 2025 financial report, showing revenue of RMB 32.857 billion for the first three quarters, up 18.61% year-on-year, and net profit surging 84.84% to RMB 12.076 billion. However, beneath the seemingly impressive figures lie multiple risks, including heavy reliance on non-recurring gains, sluggish domestic growth, and reduced R&D investment.

**Profit Growth Concerns: Over 40% from "Side Business," Sustainability in Question** Despite the 84.84% net profit growth, non-recurring gains contributed RMB 2.553 billion, primarily from divesting equity in affiliated companies. Excluding these, core net profit growth dropped to 42.51%, lagging behind peers like Pharmaron and Asymchem.

While equity investments are common in the CXO industry, Wuxi AppTec's non-recurring gains exceeding 40% of net profit highlight weaker core profitability. If investment income remains disproportionate, its valuation may shift from "R&D service leader" to a "hybrid PE/VC model," undermining confidence in sustainable earnings.

**Growth Imbalance: Near-Zero Domestic Expansion, Geopolitical Risks Mount** Regionally, revenue from Chinese clients grew just 0.5%, effectively stagnating, while U.S. and European client revenue rose 31.9% and 13.5%, respectively. This heavy reliance on overseas markets—especially the U.S.—exposes the firm to geopolitical uncertainties.

Potential U.S. policies like the *Biosecurity Act* could restrict gene-data collaborations, threatening order volumes. Though large-scale client shifts to India/Southeast Asia remain limited, supply chain diversification trends are emerging. Overdependence on a single foreign market leaves Wuxi AppTec vulnerable to policy shifts and demand volatility.

**Operational and Financial Strains: Segment Weakness, R&D Cutbacks** Internally, performance diverged: chemical and TIDES businesses grew robustly, but testing revenue flatlined, and other segments declined over 10%. Such uneven growth may weaken overall resilience.

Alarmingly, R&D spending fell 13.46% year-on-year—a red flag for an innovation-driven sector. Meanwhile, financial pressure intensified: net interest income turned to a RMB 191 million expense, and short-term borrowings skyrocketed 324.9% from end-2024, signaling debt-structure risks.

**Crossroads: Refocusing or Stagnation?** Wuxi AppTec faces critical choices: continue relying on one-off gains to polish results or strengthen core competitiveness; react passively to geopolitical waves or proactively diversify domestically. With shrinking R&D and rising costs, its ability to sustain innovation and project conversions will directly impact long-term value and market trust.